Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-26Clinical Trial Results: Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency [Phase 2]
Phase 2 trial investigating docetaxel, carboplatin, and rucaparib camsylate in metastatic castration-resistant prostate cancer with homologo…
-
CLINICAL_TRIALS trial_result · 2026-08-26Clinical Trial Results: Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating therapies for metastatic castration-resistant prostate cancer has terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2026-08-24Clinical Trial Results: A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer [Phase 1, Phase 2]
A phase 1/2 trial evaluating talazoparib in combination with temozolomide in prostate cancer has been terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2026-06-11Clinical Trial Results: Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway [Phase 2]
Phase 2 trial evaluating carboplatin in metastatic prostate cancer with homologous recombination pathway gene alterations completed with pos…
-
CLINICAL_TRIALS trial_result · 2026-04-22Clinical Trial Update: Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression [Phase 1, Phase 2]
A Phase 1/2 trial evaluating enzalutamide in combination with ribociclib in metastatic castration-resistant prostate cancer retaining retino…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer [Phase 2]
A Phase 2 clinical trial evaluated lorigerlimab in combination with docetaxel versus docetaxel alone in metastatic castration-resistant pros…
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants [Phase 1]
This document reports a completed Phase 1 clinical trial of JNJ-75229414 for metastatic castration-resistant prostate cancer.
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia [Phase 2]
Phase 2 trial of 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer with bone marrow involvement and cytopenia has been susp…
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer) [Phase 4]
This Phase 4 trial (RADIANT) compares Radium-223 Dichloride (Xofigo) versus Enzalutamide or Abiraterone in metastatic castration-resistant p…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer [Phase 1]
A Phase 1 clinical trial update evaluating the effect of multiple doses of JNJ-56021927 on the pharmacokinetics of various cytochrome P450 s…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring [Phase 1]
Phase 1 rollover study by Janssen Research & Development to continue study treatment and ongoing safety monitoring in patients with acute my…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases. [Phase 2]
Phase 2 trial of denosumab in combination with enzalutamide in progressive metastatic castration-resistant prostate cancer with bone metasta…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer [Phase 2]
A Phase 2 clinical trial evaluating a fatty acid synthase inhibitor for castration-resistant prostate cancer is currently recruiting. The sp…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer [Phase 1]
This ClinicalTrials.gov update describes a Phase 1 study of combining Lutetium-177-PSMA-617 with Carboplatin in metastatic castration-resist…
-
CLINICAL_TRIALS trial_result · 2026-04-07Clinical Trial Update: TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy [Phase 1]
Phase 1 trial update evaluating TSL2109 capsules in advanced solid tumors includes safety, tolerability, pharmacokinetics, and preliminary e…
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer [Phase 3]
Phase 3 trial comparing patient preference between cabazitaxel and docetaxel for metastatic castration-resistant prostate cancer has complet…
-
CLINICAL_TRIALS trial_result · 2026-03-31Clinical Trial Update: Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer [Phase 1]
Phase I study investigating the combination of Actinium-225 labeled J591 antibody and Lutetium-177 PSMA small molecule in progressive metast…
-
CLINICAL_TRIALS trial_result · 2026-03-23Clinical Trial Update: A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001) [Phase 1]
This clinical trial update describes a Phase 1 study of KTX-2001 in metastatic castration-resistant prostate cancer (mCRPC) and notes that S…
-
CLINICAL_TRIALS trial_result · 2026-03-19Clinical Trial Update: A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001) [Phase 1]
This trial update reports the completion of a Phase 1 study of Opevesostat (MK-5684) in Chinese participants with metastatic castration-resi…
-
CLINICAL_TRIALS trial_result · 2026-03-11Clinical Trial Update: Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response [Phase 2]
Phase 2 trial update suggests supraphysiologic testosterone priming may extend the response to darolutamide in metastatic castration-resista…
-
CLINICAL_TRIALS trial_result · 2026-03-10Clinical Trial Update: A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer [Phase 1, Phase 2]
A Phase 1/2 study evaluating tazemetostat in combination with enzalutamide or abiraterone/prednisone in advanced/metastatic prostate cancer …
-
CLINICAL_TRIALS trial_result · 2026-03-09Clinical Trial Update: Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]
Phase 2 clinical trial update on palbociclib for metastatic castration-resistant prostate cancer; the study is currently active and not recr…
-
CLINICAL_TRIALS trial_result · 2026-03-05Clinical Trial Update: Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway [Phase 1]
Phase 1 trial of DCC-3084 for MAPK-pathway driven advanced cancers has been terminated. The update notes the study status without presenting…
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: Study of INKmune in Patients With mCRPC (CaRe Prostate) [Phase 1, Phase 2]
The update notes the completion of a Phase 1/2 study of INKmune in metastatic castration-resistant prostate cancer (CaRe Prostate) sponsored…
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer [Phase 2]
Phase 2 clinical trial evaluating enzalutamide with or without radium-223 dichloride in metastatic castration-resistant prostate cancer is c…